MedTrace Logo

Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03687372 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 503

Last updated 2020-10-05

Study results available
· View outcomes & findings →

Summary

A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

Conditions

  • Common Wart

Interventions

DRUG

A-101

hydrogen peroxide topical solution 45%

OTHER

vehicle

vehicle as a topical solution

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-17
Primary Completion
2019-06-20
Completion
2019-09-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03687372 on ClinicalTrials.gov